Study of EV+P as first therapy for advanced bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well the combination of enfortumab vedotin and pembrolizumab (EV+P) works as the first treatment for people with advanced or metastatic bladder cancer or other rare urinary tract tumors. By reviewing medical records, researchers hope to learn more about the benefits of this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with advanced or metastatic bladder cancer (or a rare urinary tract tumor).
- Your cancer has spread to other parts of the body (confirmed by biopsy or imaging).
- You received EV+P as your first treatment for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) given before surgery can help patients with muscle-invasive bladder cancer or upper-tract urothelial cancer. The goal is to shrink tumors and improve outcomes before surgery removes the cancer.
This trial tests a new study drug (GB-4362) when added to the usual combination of enfortumab vedotin and pembrolizumab for advanced bladder cancer. It is for people who are about to start this standard treatment and have not had these drugs before.
This study looks at whether enfortumab vedotin (EV) affects the nervous system in people with advanced bladder cancer. It follows patients who are getting EV (alone or with immunotherapy) to see how their nerve function changes over time.
Hear when a new Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.